Azitra Q2 FY26 net loss widens to $3.3 million - AZTR News | RalliesAzitra Q2 FY26 net loss widens to $3.3 million
A
AZTR• Pipeline update
- The company reported its first preclinical ATR-COSF data showing repeat-dose delivery and anti-wrinkle activity.
- A human cosmetic application study is planned to start in Q3 2026.
- ATR-04 Phase 1/2 trial continued enrolling, with topline data from the first cohort expected in Q4 2026.
- ATR-12 enrollment is set to pause.
Q2 FY26 results and cash position
- Azitra posted a net loss of $3.3 million for the quarter ended June 30, 2026, widening from $2.9 million a year earlier.
- G&A expenses climbed to $2.1 million from $1.5 million, while R&D expenses were flat at $1.4 million.
- Cash and cash equivalents totaled $6.7 million as of June 30, 2026.
•
